Sfoglia per Autore
No role for CXCL12-G801A polymorphism in the development of extramedullary disease in acute myeloid leukemia.
2008 V. Ponziani; F. Mannelli; N. Bartalucci; G. Gianfaldoni; F. Leoni; E. Antonioli; P. Guglielmelli; S. Ciolli; A. Bosi; A. M. Vannucchi
The JAK2V617 mutation induces constitutive activation and agonist hypersensitivity in basophils from patients with polycythemia vera.
2009 Pieri L1; Bogani C; Guglielmelli P; Zingariello M; Rana RA; Bartalucci N; Bosi A; Vannucchi AM
The JAK2V617 mutation induces constitutive activation and agonist hypersensitivity in basophils of polycythemia vera.
2009 L. Pieri ; C. Bogani ; P. Guglielmelli ; M. Zingariello ; RA. Rana ; N. Bartalucci ;A Bosi ; AM. Vannucchi
Hydroxyurea does not appreciably reduce JAK2 V617F allele burden in patients with polycythemia vera or essential thrombocythemia.
2010 Antonioli E; Carobbio A; Pieri L; Pancrazzi A; Guglielmelli P; Delaini F; Ponziani V; Bartalucci N; Tozzi L; Bosi A; Rambaldi A; Barbui T; Vannucchi A
Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis
2011 Guglielmelli, Paola; Barosi, Giovanni; Rambaldi, Alessandro; Marchioli, Roberto; Masciulli, Arianna; Tozzi, Lorenzo; Biamonte, Flavia; Bartalucci, Niccolò; Gattoni, Elisabetta; Lupo, Maria Letizia; Finazzi, Guido; Pancrazzi, Alessandro; Antonioli, Elisabetta; Susini, Maria Chiara; Pieri, Lisa; Malevolti, Elisa; Usala, Emilio; Occhini, Ubaldo; Grossi, Alberto; Caglio, Silvia; Paratore, Simona; Bosi, Alberto; Barbui, Tiziano; Vannucchi, Alessandro M
Studio della via di segnalazione Akt/mTOR nelle Neoplasie Mieloproliferative Croniche
2012 N. Bartalucci
mTOR inhibitors alone and in combination with JAK2 inhibitors effectively inhibit cells of myeloproliferative neoplasms.
2013 Bogani C;Bartalucci N;Martinelli S;Tozzi L;Guglielmelli P;Bosi A;Vannucchi AM.
Rationale for targeting the PI3K/Akt/mTOR pathway in myeloproliferative neoplasms.
2013 Bartalucci N;Guglielmelli P;Vannucchi AM
Co-targeting the PI3K/mTOR and JAK2 signalling pathways produces synergistic activity against myeloproliferative neoplasms.
2013 Bartalucci N;Tozzi L;Bogani C;Martinelli S;Rotunno G;Villeval JL;Vannucchi AM
JAK PI3K/mTOR COMBINATION THERAPY
2013 Alessandro M. Vannucchi; Costanza Bogani; Niccolò Bartalucci
Preclinical models for drug selection in myeloproliferative neoplasms.
2013 Bartalucci N;Bogani C;Vannucchi AM
Calreticulin mutation-specific immunostaining in myeloproliferative neoplasms: Pathogenetic insight and diagnostic value
2014 Vannucchi, A.M.; Rotunno, G.; Bartalucci, N.; Raugei, G.; Carrai, V.; Balliu, M.; Mannarelli, C.; Pacilli, A.; Calabresi, L.; Fjerza, R.; Pieri, L.; Bosi, A.; Manfredini, R.; Guglielmelli, P.
Calreticulin mutation-specific immunostaining in myeloproliferative neoplasms: pathogenetic insight and diagnostic value.
2014 Vannucchi AM;Rotunno G;Bartalucci N;Raugei G;Carrai V;Balliu M;Mannarelli C;Pacilli A;Calabresi L;Fjerza R;Pieri L;Bosi A;Manfredini R;Guglielmelli P
Calreticulin: a new horizon for the testing and treatment of myeloproliferative neoplasms.
2014 Guglielmelli P;Bartalucci N;Rotunno G;Vannucchi AM
Rationale for combination therapies in myelofibrosis
2015 Vannucchi, Alessandro M; Bartalucci, Niccolo; Pieri, Lisa; Guglielmelli, Paola
Novel insights into myelofibrosis pathophysiology and treatment
2015 Sdan Verstovsek; Ben Y Zhang; Naseema Gangat; Francesco Passamonti; Domenica Caramazza; Barbara Mora; Margherita Maffioli; Paola Guglielmelli; Giada Rorunno; Annalisa Pacilli; Carmela Mannarelli; Holly L Geyer; Ruben A Mesa; Giovanni Barosi; Vittorio Rosti; Hans Carl Hasselbach; Kate J Newberry; Francisco Cervantes; Arturo Pereira; Alessandro M Vannucchi; Niccolò Bartalucci; Lisa Pieri; H Joachim Deeg; Olga Sala-Torra; Bart L Scott
Evaluation of plitidepsin in patients with primary myelofibrosis and post polycythemia vera/essential thrombocythemia myelofibrosis: results of preclinical studies and a phase II clinical trial
2015 Pardanani, A; Tefferi, A; Guglielmelli, P; Bogani, C; Bartalucci, N; Rodríguez, J; Extremera, S; Pérez, I; Alfaro, V; Vannucchi, A M
Endothelial-to-Mesenchymal Transition in Bone Marrow and Spleen of Primary Myelofibrosis
2017 Erba, Benedetta Gaia; Gruppi, Cristian; Corada, Monica; Pisati, Federica; Rosti, Vittorio; Bartalucci, Niccoloâ ; Villeval, Jean-Luc; Vannucchi, Alessandro Maria; Barosi, Giovanni; Balduini, Alessandra; Dejana, Elisabetta
Inhibitors of the PI3K/mTOR pathway prevent STAT5 phosphorylation in JAK2V617F mutated cells through PP2A/ CIP2A axis
2017 Bartalucci, Niccolã²; Calabresi, Laura; Balliu, Manjola; Martinelli, Serena; Rossi, Maria Caterina; Villeval, Jean Luc; Annunziato, Francesco; Guglielmelli, Paola; Vannucchi, Alessandro M.
Calreticulin affects hematopoietic stem/progenitor cell fate by impacting erythroid and megakaryocytic differentiation
2017 Salati, Simona; Prudente, Zelia; Genovese, Elena; Pennucci, Valentina; Rontauroli, Sebastiano; Bartalucci, Niccolo'; Mannarelli, Carmela; Ruberti, Samantha; Zini, Roberta; Rossi, Chiara; Bianchi, Elisa; Guglielmelli, Paola; Tagliafico, Enrico; Vannucchi, Alessandro M; Manfredini, Rossella
Titolo | Data di pubblicazione | Autore(i) | File |
---|---|---|---|
No role for CXCL12-G801A polymorphism in the development of extramedullary disease in acute myeloid leukemia. | 2008 | V. Ponziani; F. Mannelli; N. Bartalucci; G. Gianfaldoni; F. Leoni; E. Antonioli; P. Guglielmelli; S. Ciolli; A. Bosi; A. M. Vannucchi | |
The JAK2V617 mutation induces constitutive activation and agonist hypersensitivity in basophils from patients with polycythemia vera. | 2009 | Pieri L1; Bogani C; Guglielmelli P; Zingariello M; Rana RA; Bartalucci N; Bosi A; Vannucchi AM | |
The JAK2V617 mutation induces constitutive activation and agonist hypersensitivity in basophils of polycythemia vera. | 2009 | L. Pieri ; C. Bogani ; P. Guglielmelli ; M. Zingariello ; RA. Rana ; N. Bartalucci ;A Bosi ; AM. Vannucchi | |
Hydroxyurea does not appreciably reduce JAK2 V617F allele burden in patients with polycythemia vera or essential thrombocythemia. | 2010 | Antonioli E; Carobbio A; Pieri L; Pancrazzi A; Guglielmelli P; Delaini F; Ponziani V; Bartalucci N; Tozzi L; Bosi A; Rambaldi A; Barbui T; Vannucchi A | |
Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis | 2011 | Guglielmelli, Paola; Barosi, Giovanni; Rambaldi, Alessandro; Marchioli, Roberto; Masciulli, Arianna; Tozzi, Lorenzo; Biamonte, Flavia; Bartalucci, Niccolò; Gattoni, Elisabetta; Lupo, Maria Letizia; Finazzi, Guido; Pancrazzi, Alessandro; Antonioli, Elisabetta; Susini, Maria Chiara; Pieri, Lisa; Malevolti, Elisa; Usala, Emilio; Occhini, Ubaldo; Grossi, Alberto; Caglio, Silvia; Paratore, Simona; Bosi, Alberto; Barbui, Tiziano; Vannucchi, Alessandro M | |
Studio della via di segnalazione Akt/mTOR nelle Neoplasie Mieloproliferative Croniche | 2012 | N. Bartalucci | |
mTOR inhibitors alone and in combination with JAK2 inhibitors effectively inhibit cells of myeloproliferative neoplasms. | 2013 | Bogani C;Bartalucci N;Martinelli S;Tozzi L;Guglielmelli P;Bosi A;Vannucchi AM. | |
Rationale for targeting the PI3K/Akt/mTOR pathway in myeloproliferative neoplasms. | 2013 | Bartalucci N;Guglielmelli P;Vannucchi AM | |
Co-targeting the PI3K/mTOR and JAK2 signalling pathways produces synergistic activity against myeloproliferative neoplasms. | 2013 | Bartalucci N;Tozzi L;Bogani C;Martinelli S;Rotunno G;Villeval JL;Vannucchi AM | |
JAK PI3K/mTOR COMBINATION THERAPY | 2013 | Alessandro M. Vannucchi; Costanza Bogani; Niccolò Bartalucci | |
Preclinical models for drug selection in myeloproliferative neoplasms. | 2013 | Bartalucci N;Bogani C;Vannucchi AM | |
Calreticulin mutation-specific immunostaining in myeloproliferative neoplasms: Pathogenetic insight and diagnostic value | 2014 | Vannucchi, A.M.; Rotunno, G.; Bartalucci, N.; Raugei, G.; Carrai, V.; Balliu, M.; Mannarelli, C.; Pacilli, A.; Calabresi, L.; Fjerza, R.; Pieri, L.; Bosi, A.; Manfredini, R.; Guglielmelli, P. | |
Calreticulin mutation-specific immunostaining in myeloproliferative neoplasms: pathogenetic insight and diagnostic value. | 2014 | Vannucchi AM;Rotunno G;Bartalucci N;Raugei G;Carrai V;Balliu M;Mannarelli C;Pacilli A;Calabresi L;Fjerza R;Pieri L;Bosi A;Manfredini R;Guglielmelli P | |
Calreticulin: a new horizon for the testing and treatment of myeloproliferative neoplasms. | 2014 | Guglielmelli P;Bartalucci N;Rotunno G;Vannucchi AM | |
Rationale for combination therapies in myelofibrosis | 2015 | Vannucchi, Alessandro M; Bartalucci, Niccolo; Pieri, Lisa; Guglielmelli, Paola | |
Novel insights into myelofibrosis pathophysiology and treatment | 2015 | Sdan Verstovsek; Ben Y Zhang; Naseema Gangat; Francesco Passamonti; Domenica Caramazza; Barbara Mora; Margherita Maffioli; Paola Guglielmelli; Giada Rorunno; Annalisa Pacilli; Carmela Mannarelli; Holly L Geyer; Ruben A Mesa; Giovanni Barosi; Vittorio Rosti; Hans Carl Hasselbach; Kate J Newberry; Francisco Cervantes; Arturo Pereira; Alessandro M Vannucchi; Niccolò Bartalucci; Lisa Pieri; H Joachim Deeg; Olga Sala-Torra; Bart L Scott | |
Evaluation of plitidepsin in patients with primary myelofibrosis and post polycythemia vera/essential thrombocythemia myelofibrosis: results of preclinical studies and a phase II clinical trial | 2015 | Pardanani, A; Tefferi, A; Guglielmelli, P; Bogani, C; Bartalucci, N; Rodríguez, J; Extremera, S; Pérez, I; Alfaro, V; Vannucchi, A M | |
Endothelial-to-Mesenchymal Transition in Bone Marrow and Spleen of Primary Myelofibrosis | 2017 | Erba, Benedetta Gaia; Gruppi, Cristian; Corada, Monica; Pisati, Federica; Rosti, Vittorio; Bartalucci, Niccoloâ ; Villeval, Jean-Luc; Vannucchi, Alessandro Maria; Barosi, Giovanni; Balduini, Alessandra; Dejana, Elisabetta | |
Inhibitors of the PI3K/mTOR pathway prevent STAT5 phosphorylation in JAK2V617F mutated cells through PP2A/ CIP2A axis | 2017 | Bartalucci, Niccolã²; Calabresi, Laura; Balliu, Manjola; Martinelli, Serena; Rossi, Maria Caterina; Villeval, Jean Luc; Annunziato, Francesco; Guglielmelli, Paola; Vannucchi, Alessandro M. | |
Calreticulin affects hematopoietic stem/progenitor cell fate by impacting erythroid and megakaryocytic differentiation | 2017 | Salati, Simona; Prudente, Zelia; Genovese, Elena; Pennucci, Valentina; Rontauroli, Sebastiano; Bartalucci, Niccolo'; Mannarelli, Carmela; Ruberti, Samantha; Zini, Roberta; Rossi, Chiara; Bianchi, Elisa; Guglielmelli, Paola; Tagliafico, Enrico; Vannucchi, Alessandro M; Manfredini, Rossella |
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile